cholesteryl hemi-4-oxaglutarate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cholesteryl hemi-4-oxaglutarate
• 英文别名: cholesterol-diglycolic acid；cholesteryl diglycolate；2-[2-[[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-2-oxoethoxy]acetic acid
• 化学式: C₃₁H₅₀O₅
• 分子量: 502.735
• InChiKey: YYNWUYARKNCWPZ-MIXBDBMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  cholesteryl hemi-4-oxaglutarate 、 多西他赛 在 4-二甲氨基吡啶 、 N,N'-二异丙基碳二亚胺 作用下， 以 氯仿 为溶剂， 生成 docetaxel-diglycolate-cholesterol
  参考文献：
  名称：

  [EN] IMPROVED NANOPARTICLE DELIVERY SYSTEMS
  [FR] SYSTÈMES AMÉLIORÉS D'ADMINISTRATION DE NANOPARTICULES

  摘要：

  本文描述的纳米粒子组合物包括治疗剂的前药组合，与给予这些治疗剂的自由形式组合相比，能够实现增强的治疗效果。

  公开号：

  WO2017011685A1
• 作为产物：
  描述：

  二甘醇酐 、 胆固醇 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以35%的产率得到cholesteryl hemi-4-oxaglutarate
  参考文献：
  名称：

  Lipids, lipid compositions, and methods of using them

  摘要：

  揭示了用于将生物活性剂量有效传递至肝脏、肿瘤和/或其他细胞或组织的配方和优化协议。还提供了具有式(I)的阳离子脂质化合物的组成物和用途。该发明还涉及具有式(XI)的隐身脂质的组成物和用途。此外，还提供了制备这类化合物、组成物和配方的方法，以及利用这类化合物、组成物和配方将生物活性剂传递至细胞和/或组织的方法和用途。

  公开号：

  US09301923B2

文献信息

• Nanoparticle delivery systems
  申请人：CELATOR PHARMACEUTICALS, INC.

  公开号：US10285951B2

  公开（公告）日：2019-05-14

  Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.

  本文所述的纳米颗粒组合物包括治疗剂的原药组合，与施用这些治疗剂的游离形式组合时观察到的治疗效果相比，这些原药组合可达到更强的治疗效果。
• Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates
  作者：Steven M. Ansell、Sharon A. Johnstone、Paul G. Tardi、Lily Lo、Sherwin Xie、Yu Shu、Troy O. Harasym、Natashia L. Harasym、Laura Williams、David Bermudes、Barry D. Liboiron、Walid Saad、Robert K. Prud’homme、Lawrence D. Mayer

  DOI：10.1021/jm800002y

  日期：2008.6.1

  A series of paclitaxel prodrugs designed for formulation in lipophilic nanoparticles are described. The hydrophobicity of paclitaxel was increased by conjugating a succession of increasingly hydrophobic lipid anchors to the drug using succinate or diglycolate cross-linkers. The prodrugs were formulated in well defined block copolymer-stabilized nanoparticles. These nanoparticles were shown to have an elimination half-life of approximately 24 h in vivo. The rate at which the prodrug was released from the nanoparticles could be controlled by adjusting the hydrophobicity of the lipid anchor, resulting in release half-lives ranging from 1 to 24 h. The diglycolate and succinate cross-linked prodrugs were 1-2 orders of magnitude less potent than paclitaxel in vitro. Nanoparticle formulations of the succinate prodrugs showed no evidence of efficacy in HT29 human colorectal tumor xenograph models. Efficacy of diglycolate prodrug nanoparticles increased as the anchor hydrophobicity increased. Long circulating diglycolate prodrug nanoparticles provided significantly enhanced therapeutic activity over commercially formulated paclitaxel at the maximum tolerated dose.
• Bis antennae amphiphilic cyclodextrins: the first examples
  作者：Mayeul Collot、Maria Isabel Garcia-Moreno、Christophe Fajolles、Michel Roux、Laurent Mauclaire、Jean-Maurice Mallet

  DOI：10.1016/j.tetlet.2007.09.020

  日期：2007.11

  Methylated 6A,6D-diamino 6A,6D-dideoxy beta-cyclodextrin 4 was coupled with three cholesterol substituted glutaric or succinic acids 5-7 to give amphiphilic cyclodextrins 1-3 with good yields. The succinic acid derivative 1, a typical member of this new Family, has shown good compatibility with phosphatidyl choline monolayer and bilayer as confirmed by deuterium magnetic nuclear resonance (H-2 NMR). (C) 2007 Elsevier Ltd. All rights reserved.
• IMPROVED NANOPARTICLE DELIVERY SYSTEMS
  申请人：CELATOR PHARMACEUTICALS, INC.

  公开号：US20180207104A1

  公开（公告）日：2018-07-26

  Nanopaiticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
• NANOPARTICLE DELIVERY SYSTEMS
  申请人：CELATOR PHARMACEUTICALS, INC.

  公开号：US20190209484A1

  公开（公告）日：2019-07-11

  Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.